ArticleFrontiers in oncology2025
Machine learning modeling of cancer treatment-related cardiac events in breast cancer: utilizing dosiomics and radiomics.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A systematic review of artificial intelligence in radiotherapy associated cardiovascular toxicity.Cardio-oncology (London, England) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Personalized medicine has transformed disease management by focusing on individual characteristics, driven by advancements in genome mapping and biomarker discoveries. Objectives: This study aims to develop a predictive model for the early detection of treatment-related cardiac side effects in breast cancer patients by integrating clinical data, high-sensitivity Troponin-T (hs-TropT), radiomics, and dosiomics. The ultimate goal is to identify subclinical cardiotoxicity before clinical symptoms manifest, enabling personalized surveillance strategies. It is the first study to utilize heart-segmented dosiomics in breast cancer patients. Methods and Materials: This retrospective study included clinical, dosimetric, radiomic, and dosiomic data from 42 women with localized breast cancer. Heart-specific Troponin T levels were measured 2-3 weeks post-radiotherapy, with 14 ng/L as the cutoff. Patients were grouped on this threshold to identify potential treatment-related cardiac events. Radiomics and dosiomics were extracted using PyRadiomics. Machine learning models were optimized using the Tree-based Pipeline Optimization Tool (TPOT), identifying the gradient-boosted classification as the best-performing algorithm. Feature selection was conducted using gradient-boosted recursive feature elimination. Model performance is assessed by the area under the curve (AUC). Results: A total of 111 dosiomic and 119 radiomic features were extracted per patient. The highest predictive accuracy was achieved using clinical, dosiomic, and radiomic parameters (validation cohort-AUC = 0.96), outperforming the clinical + dosimetric model (validation cohort-AUC = 0.67). Permutation tests confirmed the non-randomness of these two models results (p <0.05). Cross-validation indicated that the clinical + dosiomic + radiomic model had a fair-to-good generalizable performance (mean AUC = 80.33 ± 21%). Discussion: This study may demonstrate that radiomics and dosiomics provide superior predictive capabilities for cardiac events in breast cancer patients compared to traditional parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.